*Internal data
**Novartis Report on Nonfinancial Matters
*** For an explanation of non-IFRS measures and reconciliation tables, see “Non-IFRS measures as defined by Novartis.”
Core research and development expense exclude impairments, amortization and certain other items.
We are a company focused on innovative medicines, working on four therapeutic areas and five technology platforms.
Novartis aims to change the course of cardiovascular, renal and metabolic disease by shifting from late crisis management to protecting hearts, kidneys and metabolism much earlier in life. Our science reimagines how we reduce risk and preserve organ function over the long term using next-generation platforms to deliver deeper, more durable benefits for patients. We seek bold, like-minded partners in CRM, uniting their breakthrough ideas with our global R&D engine, diverse technology platforms and leading dealmaking capabilities to bring transformative therapies to patients at scale.
Novartis is committed to transforming immunology by investing in breakthrough science to address the highest unmet needs. Leveraging diverse platforms like cell and gene therapy, small molecule degraders, multispecific biotherapeutics, Novartis develops therapies that target the root causes of immune diseases. As a market leader in deal-making, Novartis partners with innovators to bring game-changing solutions to patients.
Inspired to transform the lives of people with neurological diseases, Novartis applies leading science and diverse platforms—like gene, cell, and RNA therapies—to tackle the root causes of neurodegeneration, neuromuscular, and neuroinflammatory neuroimmunology disorders. Our robust pipeline targets key areas such as multiple sclerosis, Alzheimer’s, and rare neuromuscular diseases. We partner with innovators worldwide, offering deep expertise and resources to accelerate impactful solutions for patients.
Novartis is inspired to reimagine cancer care through bold innovation and collaboration. Our science leads the industry across advanced platforms like Radioligand Therapy, Biotherapeutics (including ADCs), small molecules or Cell & Gene Therapy, setting new standards in cancer care. We partner with innovators who share our vision, combining strengths to bring transformative therapies to patients worldwide.
Novartis is driven by a bold vision to transform patient outcomes by harnessing cutting-edge platforms and AI to tackle society’s toughest healthcare challenges. With deep scientific expertise across diverse modalities—including Cell & Gene Therapy, Radioligand Therapy (RLT), and xRNA—Novartis accelerates drug discovery and development through rigorous data-driven innovation and advanced AI applications. We actively seek like-minded partners to scale breakthrough therapies and platforms, leveraging our global network and proven deal-making leadership to bring game-changing solutions to patients worldwide.
We collaborate to address some of society's most challenging healthcare issues and have a unified partnering strategy fueled by clarity, agility, accountability, and efficiency.
